Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Bergstrom

Showing results (61-70 of 63) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 63 results.
Journal of Medicinal Chemistry|November 7, 1998
Clavaric acid and steroidal analogues as Ras- and FPP-directed inhibitors of human farnesyl-protein transferaseR B Lingham, K C Silverman, H Jayasuriya, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 7, 2000
Deficiency in inducible nitric oxide synthase results in reduced atherosclerosis in apolipoprotein E-deficient miceP A Detmers, M Hernandez, J Mudgett, et al.
Blood Cancer Journal|December 8, 2023
Real world data on outcomes of anti-CD38 antibody treated, including triple class refractory, patients with multiple myeloma: a multi-institutional report from the Canadian Myeloma Research Group (CMRG) DatabaseA Visram, A De La Torre, D White, et al.
Pageof 7

Showing results (61-70 of 63) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 63 results.
Journal of Medicinal Chemistry|November 7, 1998
Clavaric acid and steroidal analogues as Ras- and FPP-directed inhibitors of human farnesyl-protein transferaseR B Lingham, K C Silverman, H Jayasuriya, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 7, 2000
Deficiency in inducible nitric oxide synthase results in reduced atherosclerosis in apolipoprotein E-deficient miceP A Detmers, M Hernandez, J Mudgett, et al.
Blood Cancer Journal|December 8, 2023
Real world data on outcomes of anti-CD38 antibody treated, including triple class refractory, patients with multiple myeloma: a multi-institutional report from the Canadian Myeloma Research Group (CMRG) DatabaseA Visram, A De La Torre, D White, et al.
Pageof 7